USP22 and lung adenocarcinoma: The cisplatin sensitivity in cisplatin-resistant A549/CDDP cells was restored by USP22 inhibition in vivo and vitro. Interestingly, these results reveal the dual mechanism of USP22 involvement in cisplatin acquired resistance and inhibiting USP22 expression could enhance cisplatin sensitivity in lung adenocarcinoma.